Contrasting Atyr PHARMA (ATYR) and Its Peers

Atyr PHARMA (NASDAQ:ATYR) is one of 287 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its rivals? We will compare Atyr PHARMA to related businesses based on the strength of its profitability, risk, analyst recommendations, dividends, institutional ownership, valuation and earnings.

Profitability

This table compares Atyr PHARMA and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Atyr PHARMA	N/A	-65.35%	-49.81%
Atyr PHARMA Competitors	-4,911.69%	-198.97%	-43.98%

Risk and Volatility

Atyr PHARMA has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500. Comparatively, Atyr PHARMA’s rivals have a beta of 1.04, meaning that their average stock price is 4% more volatile than the S&P 500.

Valuation & Earnings

This table compares Atyr PHARMA and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Atyr PHARMA	$588,000.00	-$50.39 million	-2.08
Atyr PHARMA Competitors	$546.90 million	-$36.75 million	-26.10

Atyr PHARMA’s rivals have higher revenue and earnings than Atyr PHARMA. Atyr PHARMA is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Atyr PHARMA and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atyr PHARMA	0	0	3	0	3.00
Atyr PHARMA Competitors	1609	4807	12363	237	2.59

Atyr PHARMA presently has a consensus price target of $20.00, indicating a potential upside of 969.52%. As a group, “Biological products, except diagnostic” companies have a potential upside of 60.18%. Given Atyr PHARMA’s stronger consensus rating and higher probable upside, equities analysts clearly believe Atyr PHARMA is more favorable than its rivals.

Insider and Institutional Ownership

61.7% of Atyr PHARMA shares are held by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 3.7% of Atyr PHARMA shares are held by company insiders. Comparatively, 16.2% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Atyr PHARMA beats its rivals on 8 of the 13 factors compared.

Atyr PHARMA Company Profile

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.